COVID-19: Newly Published Research and CDC Data

Written by Robert W Malone MD, MS on July 27, 2023. Posted in Current News

Recently, there have been a couple of interesting papers published concerning mRNA COVID-19 vaccines. These are papers that for some reason haven’t made it to main-stream media. Let’s take a look

Factors associated with stroke after COVID-19 vaccination: a statewide analysis

Front Neurol 2023 Jun 28;14:1199745. doi: 10.3389/fneur.2023.1199745. eCollection 2023.

Abstract

Background: The objective of our study was to evaluate vaccine type, COVID-19 infection, and their association with stroke soon after COVID-19 vaccination.

Methods: In a retrospective cohort study, we estimated the 21-day post-vaccination incidence of stroke among the recipients of the first dose of a COVID-19 vaccine. We linked the Georgia Immunization Registry with the Georgia Coverdell Acute Stroke Registry and the Georgia State Electronic Notifiable Disease Surveillance System data to assess the relative risk of stroke by the vaccine type.

Results: Approximately 5 million adult Georgians received at least one COVID-19 vaccine between 1 December 2020 and 28 February 2022: 54 percent received BNT162b2, 41 percent received mRNA-1273, and five percent received Ad26.COV2.S.

Those with concurrent COVID-19 infection within 21 days post-vaccination had an increased risk of ischemic (OR = 8.00, 95 percent CI: 4.18, 15.31) and hemorrhagic stroke (OR = 5.23, 95 percent CI: 1.11, 24.64) with no evidence for interaction between the vaccine type and concurrent COVID-19 infection.

The 21-day post-vaccination incidence of ischemic stroke was 8.14, 11.14, and 10.48 per 100,000 for BNT162b2, mRNA-1273, and Ad26.COV2.S recipients, respectively. After adjusting for age, race, gender, and COVID-19 infection status, there was a 57 percent higher risk (OR = 1.57, 95 percent CI: 1.02, 2.42) for ischemic stroke within 21 days of vaccination associated with the Ad26.COV2.S vaccine compared to BNT162b2; there was no difference in stroke risk between mRNA-1273 and BNT162b2…

Overall, 473 (9.498 per 100 thousand) had ischemic stroke, and 87 (1.747 per 100 thousand) subjects had developed hemorrhagic stroke within 21 days post-vaccination.

The 21-day post-vaccination incidence of ischemic stroke was 8.14, 11.14, and 10.48 per 100,000 for BNT162b2, mRNA-1273, and Ad26.COV2.S recipients, respectively; after adjusting for age, race, gender, and COVID-19 infection status, there was a 57 percent higher risk (OR = 1.57, 95 percent CI: 1.02, 2.42) for ischemic stroke within 21 days of vaccination associated with Ad26.COV2.S vaccine compared to BNT162b2 (Table 2).

There was no difference seen in the risk of stroke between mRNA-1273 compared to BNT162b2. After adjusting for age, race, gender, and COVID-19 infection status, those with concurrent COVID-19 infection had an increased risk of ischemic (OR = 8.00, 95 percent CI: 4.18, 15.31) and hemorrhagic stroke (OR = 5.23, 95 percent CI: 1.11, 24.64).

There was no statistical evidence for an interaction between vaccine type and concurrent COVID-19 infection.

In plain language, 5.6 in 1000 people had a stroke after “vaccination” within a 21 day period. The J&J product was associated with more strokes than the Pfizer or Moderna products.

Those who were “vaccinated” with concurrent COVID-19 infections had an increased risk of either type of stroke.

It was noted that COVD-19 infection also can increase the risk of stroke (of course, both infection and the “vaccines” produce spike protein!), what isn’t noted is that the difference between severity of variants (alpha to omicron and beyond) is significant.

The data used to make this claim is outdated.

See more here substack.com

Please Donate Below To Support Our Ongoing Work To Expose The Lies About Covid 19

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Trackback from your site.